Morepen Laboratories Expands API and CDMO Capacity to 614 KL Ahead of Schedule
Morepen Laboratories Limited has completed the first phase of its manufacturing capacity expansion programme ahead of the previously indicated timeline. The company has increased its installed reactor capacity for API and CDMO manufacturing from 535 KL to 614 KL.
The development strengthens Morepen Laboratories’ manufacturing capabilities and is expected to support the scale-up of commercial CDMO supplies, its existing API business and future customer programmes.
Morepen Laboratories Capacity Expansion
According to the company’s exchange filing dated September 7, 2026, the first phase of the manufacturing capacity expansion has been completed ahead of schedule.
The company’s installed reactor capacity has increased by 79 KL, from 535 KL to 614 KL. This represents an increase of approximately 14.8% in installed reactor capacity.
The expanded capacity is intended to strengthen the company’s manufacturing readiness as it scales up commercial CDMO supplies.
Why Morepen Laboratories is in Focus
Morepen Laboratories is in focus after announcing the early completion of the first phase of its API and CDMO manufacturing capacity expansion.
The increase in reactor capacity provides additional manufacturing headroom for the company as it looks to scale its commercial CDMO operations.
The key points attracting investor attention are:
- Capacity increased from 535 KL to 614 KL
- 79 KL of additional reactor capacity added
- First phase completed ahead of schedule
- Additional capacity to support commercial CDMO supplies
- Capacity will also support the company’s existing API business
- Infrastructure is being developed to support future customer programmes
- Company is targeting a larger and scalable manufacturing platform
The early completion is an operational positive, although the financial benefit will ultimately depend on capacity utilisation and the pace at which commercial CDMO programmes ramp up.
API and CDMO Business to Benefit
The expanded reactor capacity is expected to support Morepen Laboratories across both its API and CDMO businesses.
For the API business, additional manufacturing capability can provide greater flexibility in supporting existing requirements.
For CDMO operations, the capacity expansion is particularly relevant because the company is working towards scaling up commercial supplies and developing longer-duration customer relationships.
The company said the expansion is part of its strategy to build a larger, scalable, and globally compliant manufacturing platform.
What Does the 614 KL Capacity Mean for Morepen Laboratories?
The increase from 535 KL to 614 KL gives Morepen Laboratories additional production capacity without waiting for the completion of the entire expansion programme.
The 79 KL addition represents approximately a 14.8% increase over the earlier installed reactor capacity.
However, installed capacity by itself does not immediately translate into higher revenue. Investors will need to track how quickly the new capacity is utilised and whether it leads to increased commercial production.
The key metrics to monitor in upcoming quarters will therefore include capacity utilisation, CDMO order wins, commercial supply ramp-up, API volumes and revenue growth.
Management’s Strategic Outlook
Morepen Laboratories described the completion of the first phase as an important milestone in its strategy to develop a larger and scalable manufacturing platform.
The company’s stated focus is on:
- Building long-duration customer partnerships
- Scaling commercial CDMO supplies
- Supporting the existing API business
- Expanding manufacturing capabilities
- Developing a globally compliant manufacturing platform
- Supporting sustained growth in API and CDMO businesses
The company’s ability to convert this additional manufacturing capacity into long-term customer contracts and commercial supplies will be an important factor for future growth.
Investor Takeaway
The completion of Morepen Laboratories’ first phase of capacity expansion ahead of schedule is a positive operational development.
The increase in reactor capacity from 535 KL to 614 KL provides the company with additional manufacturing capacity to support its API business and the scale-up of commercial CDMO supplies.
For investors, the next stage will be more important: how quickly the additional capacity gets utilised and how much incremental revenue and profitability it generates.
The announcement should therefore be viewed as a capacity and business-growth development rather than an immediate earnings trigger.
Morepen Laboratories Stock News: Key Highlights
- Company: Morepen Laboratories Limited
- NSE Symbol: MOREPENLAB
- BSE Code: 500288
- Announcement date: September 7, 2026
- Expansion: First phase of manufacturing capacity expansion
- Previous capacity: 535 KL
- New capacity: 614 KL
- Capacity addition: 79 KL
- Increase: Approximately 14.8%
- Businesses: API and CDMO
- Completion: Ahead of schedule
- Key growth driver: Scale-up of commercial CDMO supplies
- Investor focus: Capacity utilisation, CDMO ramp-up and revenue growth
This article is based on Morepen Laboratories Limited’s stock exchange announcement dated September 7, 2026. The information is for informational purposes only and should not be considered investment advice.